Sanofi US News

Patients treated with Lovenox® (enoxaparin sodium injection) were also less likely to be readmitted to hospital within 90 days

No human vaccine against West Nile virus today; Disease endemic in the United States

Menactra® meningococcal conjugate vaccine approved for use in children 2 years through 10 years of age

Clinical study demonstrates breakthrough dose-sparing formulation that increases stockpile capacities and expands potential production capacities to billions of doses in a pandemic situation

Sanofi pasteur Leads the Way in Influenza Vaccine Supply and Pandemic Preparedness

Sanofi pasteur continues to join with the U.S. government in enhancing the nation’s pandemic preparedness to protect public health

sanofi pasteur receives first U.S. license for a vaccine against avian influenza in humans marking an important milestone in pandemic preparedness

If approved, Pentacel vaccine would be the first pediatric combination vaccine in the U.S. to immunize against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib)

Record production capabilities strengthen sanofi pasteur’s global leadership in the fight against seasonal influenza and place the company at the forefront of pandemic readiness

The PREVAIL study showed that in acute ischemic stroke patients treated with Lovenox, the risk of having a VTE was lowered by a significant 43% with no statistically significant increase in clinically important bleedings when compared to UFH

First Rimonabant Trial with HbA1c as a Primary Endpoint

Sanofi pasteur able to produce additional vaccine to meet customer demand

New pre-pandemic vaccine will provide additional level of preparedness

Sales Growth of 2.6% on a Comparable Basis(1)

Comparative Clinical Trial Results Announced for the Treatment of Nasolabial Folds at the 2006 American Society of Dermatologic Surgery (ASDS) Annual Meeting

Taxotere(R)-based regimen demonstrates a significantly longer progression free survival and 29 percent reduction in the risk of mortality in patients with inoperable locally advanced head and neck cancer

New formulation provides non-impairing symptom relief for pediatric populations

As communicated by CDC, majority of supply will be available in October and November; sanofi pasteur shipped one-third of influenza vaccine planned for 2006-2007 season

Flu vaccine based on new technology within U.S. Government Preparedness Program

Shipment of Fluzone Influenza Virus Vaccine to U.S. Market Begins

Expands PLAVIX Indication to include patients with any acute coronary syndromes (ACS)

12 Million Men in U.S. at Risk for this Fragile Bone Disease

Results extending the role of AMBIEN CR in the treatment of insomnia presented at the 2006 CINP (Collegium Internationale Neuro-Psychopharmacologicum) 25th Biennial Congress

Complications from DVT kill up to 200,000 Americans every year, yet the risk of DVT can be reduced

Thrombosis Management Clinical Effectiveness Initiative(R) (CEI) Study Demonstrates Cost Savings of More Than $1,000 Per Discharge With Enoxaparin

Type 2 Diabetes Patients Using a New Insulin Dosing Strategy Achieved a Mean A1C of 6.6% after 24 Weeks of Combination Therapy with Rapid-Acting Apidra(R)

Findings show demonstrated overall survival with less febrile neutropenia for Taxotere(R) versus vinca-alkaloid regimens

430 abstracts from studies involving Taxotere(R) or Eloxatin(R) accepted at the meeting's scientific sessions